SCHEMBL7141098

SCHEMBL7141098

Cc1ccc(S(=O)(=O)N(CCc2ccccc2)C2CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.53
CNR2 P34972 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
CD4 P01730 2/20 0.48
SORT1 Q99523 1/20 0.48
LMNA P02545 3/20 0.48
POLB P06746 1/20 0.48
ALDH1A1 P00352 2/20 0.47
TSHR P16473 1/20 0.47
CXCR4 P61073 2/20 0.47
ACHE P22303 2/20 0.47
BACE1 P56817 2/20 0.47
HTR2A P28223 1/20 0.47
CHRM2 P08172 1/20 0.46
CHRM3 P20309 1/20 0.46
HTR6 P50406 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142813 0.92 HTR2A (0.56) OPRM1CXCR4ACHEHTR2ACHRM2
SCHEMBL7141347 0.90 CHRM4 (0.52) OPRM1SMN1; SMN2LMNACXCR4HTR2A
SCHEMBL7141075 0.90 HTT (0.56) OPRM1ALDH1A1ACHEBACE1HTR2A
SCHEMBL1682262 0.83 CXCR4 (0.51) OPRM1CNR2SMN1; SMN2CD4SORT1
SCHEMBL7142247 0.81 NPSR1 (0.56) OPRM1SMN1; SMN2CD4SORT1LMNA
SCHEMBL14518699 0.80 CNR2 (0.58) CNR2LMNAALDH1A1HTR2A
SCHEMBL14045066 0.80 HTR6 (0.48) OPRM1SMN1; SMN2LMNAALDH1A1CXCR4
SCHEMBL16757379 0.76 KMT2A (0.67) OPRM1LMNAPOLBALDH1A1ACHE
SCHEMBL13200793 0.76 HTR2A (0.60) CNR2ALDH1A1HTR2A
SCHEMBL1682283 0.76 CXCR4 (0.51) OPRM1CNR2ALDH1A1CXCR4HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US claimed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP claimed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO claimed
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US disclosed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP disclosed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176461-A1 Aminopiperidines SLC1A2, SLC6A4, SLC1A1 OPRM1 242/4885CNR2 451/4885SMN1; SMN2 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.